Loading…
Listed Indian subsidiary of Pfizer selling branded pharmaceuticals, vitamins and vaccines domestically.
Listed Indian subsidiary of Pfizer selling branded pharmaceuticals, vitamins and vaccines domestically.
Majority-owned by Pfizer Inc, it sells long-standing local brands and Pfizer's global products through wholesalers to pharmacies and hospitals. Sales depend on doctors' prescriptions and on Indian price controls on essential medicines, which set ceilings for many drugs.
In one line: Pfizer's Indian pharma subsidiary.
Moat: narrow (brand). Established consumer trust in legacy brands like Becosules, though the portfolio is narrower than global Pfizer.
Headquarters: Mumbai, India · Founded: 1950 · Employees: 1,417
Size Pfizer (PFIZER.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.87B, the 385th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹3,856 on 6 Nov 2026.
Performance Over six months the shares fell 18.8%, against -5.8% for the median peer and 0.0% for the India market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 11.8% over the last twelve months (peer median +11.9%); the operating margin is 34.5% (peer median 17.3%).
Valuation It trades at 21.5× forward earnings against a peer median of 24.4× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 35.4 points above its cost of capital (13.1% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹26.5B | ₹25.2B | ₹22.8B | ₹21.9B | ₹24.2B |
| Revenue growth | — | +10% | +4% | -10% | — |
| Gross profit | ₹12.6B | ₹11.5B | ₹9.86B | ₹9.37B | ₹10.6B |
| EBITDA | ₹9.73B | ₹9.21B | ₹7.58B | ₹6.54B | ₹8.28B |
| Net income | ₹8.59B | ₹7.22B | ₹7.68B | ₹5.51B | ₹6.24B |
| Free cash flow | n/a | ₹11.2B | ₹7.71B | ₹3.66B | ₹3.61B |
| Capital expenditure | n/a | ₹252M | ₹282M | ₹189M | ₹650M |
| Total debt | ₹1.97B | ₹702M | ₹1.08B | ₹945M | ₹1.34B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pfizer PFIZER.NS | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% |
| Abbott India ABBOTINDIA.NS | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% |
| Sanofi India SANOFI.NS | $800M | -3% | -6% | 26% | 19.9× | 16.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PFIZER.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -2.7% | 9th highest of 21 |
| 6-month return | -18.8% | -5.8% | 4th lowest of 21 |
| Distance from 52-week high | -27.8% | -27.2% | 11th highest of 21 |
| Revenue growth (TTM) | +11.8% | +11.9% | 11th highest of 21 |
| Operating margin | 34.5% | 17.3% | 3rd highest of 21 |
| Forward P/E | 21.5× | 24.4× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 11.2% | 9.0% | 8th least demanding of 15 |
| Growth delivered (Del g) | +2.4% | +13.2% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | +8.8 pp | -6.8 pp | 5th most demanding of 15 |
| ROIC minus cost of capital | +35.4 pp | +0.4 pp | highest of 21 |
| EV / EBITDA | 15.1× | 18.7× | 4th cheapest of 10 |
| Net debt / EBITDA | -3.1× | -0.8× | least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.88B | -13% | -6% | 8% | 22.5× | 0.1% | +0.5% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |